Journal
TRENDS IN MOLECULAR MEDICINE
Volume 13, Issue 6, Pages 252-259Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2007.04.002
Keywords
-
Funding
- NCI NIH HHS [U01-CA84292-06] Funding Source: Medline
- NIDDK NIH HHS [DK 73802] Funding Source: Medline
Ask authors/readers for more resources
Recent studies demonstrate that the mammalian target of rapamycin (mTOR) and its effector, S6 kinase 1 (S6K1), lie at the crossroads of a nutrient-hormonal signaling network that is involved in specific pathological responses, including obesity, diabetes and cancer. mTOR exists in two complexes: mTOR Complex1, which is rapamycin-sensitive and phosphorylates S6K1 and initiation factor 4E binding proteins (4E-BPs), and mTOR Complex2, which is rapamycin-insensitive and phosphorylates protein kinase B (PKB, also known as Akt). Both mTOR complexes are stimulated by mitogens, but only mTOR Complex1 is under the control of nutrient and energy inputs. Thus, to orchestrate the control of homeostatic responses, mTOR Complex1 must integrate signals from distinct cues. Here, we review recent findings concerning the regulation and pathophysiology associated with mTOR Complex1 and S6K1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available